

An evidence-based scoring system for prioritizing mosaic aneuploid embryos following preimplantation genetic screening (PGS)

Francesca Romana Grati¹, Gloria Gallazzi¹, Lara Branca¹, Federico Maggi¹, Giuseppe Simoni¹, Yuval Yaron²

¹ R&D, Cytogenetics and Medical Genetics Unit, TOMA Advanced Biomedical Assays S.p.A., Busto Arsizio (VA), Italia

² Prenatal Genetic Diagnosis Unit, Genetic Institute, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Abstract

During current PGS practice aneuploid embryos are occasionally encountered and often these are the only embryos available for transfer. It is currently unclear whether mosaic embryos should be considered for transfer. General guidelines have been suggested by PGDIS and COGEN, but they do not provide a clear scoring system.

During the talk an evidence-based scoring system for prioritizing mosaic aneuploid embryos for transfer will be presented. It is based on a retrospective analysis of cytogenetic and molecular analysis in 72,472 chorionic villi samples and 3806 products of conception to assess the likelihood that mosaic aneuploidy in the placenta will result in fetal aneuploidy, clinically significant uniparental disomy or miscarriage. This tool based on the risk for these adverse outcomes can assist fertility experts in making clinical decisions and patient counseling.